[CAS NO. 192314-93-5] Iclaprim
PRODUCTS SPECIFICATIONS [192314-93-5]
DESCRIPTION [192314-93-5]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 354.40 |
| Molecular Formula | C19H22N4O3 |
| SMILES | NC1=NC=C(CC2=C3C=CC(C4CC4)OC3=C(OC)C(OC)=C2)C(N)=N1 |
1 Publications Citing Use of MCE
Summary
Iclaprim is a new selective bacterial Dihydrofolate inhibitor, which can inhibit the growth of S. aureus ( MRSA ) with an MIC 90 of 0.06 μg/mL.
IC50 & Target
Dihydrofolate [1]
In Vitro
Iclaprim inhibits the growth of S. aureus (MRSA) with an MIC 90 of 0.06 μg/mL [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00303550 | Arpida AG |
Skin Diseases, Bacterial
|
March 2006 | Phase 3 |
| NCT00299520 | Arpida AG |
Complicated Skin and Skin Structure Infection
|
June 2005 | Phase 3 |
| NCT02607618 | Motif Bio |
Skin Structures and Soft Tissue Infections
|
November 2015 | Phase 3 |
| NCT00543608 | Arpida AG |
Hospital-Acquired Pneumonia|Ventilator-Associated Pneumonia|Health-Care-Associated Pneumonia
|
November 2007 | Phase 2 |
| NCT02600611 | Motif Bio |
Skin Structures and Soft Tissue Infections
|
November 1, 2015 | Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 30 mg/mL ( 84.65 mM ; Need ultrasonic and warming)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.8217 mL | 14.1084 mL | 28.2167 mL |
| 5 mM | 0.5643 mL | 2.8217 mL | 5.6433 mL |
| 10 mM | 0.2822 mL | 1.4108 mL | 2.8217 mL |
References
Synonyms